doctor Find a doctor
OR

You are here

Press Releases

Matthew Kulke, MD, Joins Boston Medical Center, Boston University School of Medicine

November 21, 2017

For More Information, Contact:
Jenny Eriksen Leary
Office of Communications
617-638-6841
[email protected]

Matthew Kulke, MD, Joins Boston Medical Center, Boston University School of Medicine

(Boston) – Nov. 21, 2017 – Matthew Kulke, MD, will become the Chief of the Section of Hematology/Oncology in the Department of Medicine at Boston Medical Center (BMC) and Zoltan Kohn Professor of Medicine at Boston University School of Medicine, effective March 1, 2018. In addition, Dr. Kulke will serve as Deputy Director of the BU-BMC Cancer Center and Medical Director of the Clinical Cancer Center at BMC.

Dr. Kulke is currently the Director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. A leader in the research and treatment of neuroendocrine tumors, he has received numerous awards for his accomplishments as a clinical investigator and provider of compassionate care to patients.

He has led national and international clinical trials to identify new therapeutic and diagnostic approaches to neuroendocrine tumors and gastrointestinal malignancies. In addition, he has published more than 100 peer-reviewed articles about neuroendocrine tumors.

Dr. Kulke received his undergraduate degree from Princeton University, his MD from University of California, San Francisco School of Medicine, and a master's degree in medical science from Harvard Medical School.

He completed his residency at Brigham and Women's Hospital in Internal Medicine and a fellowship in medical oncology at Dana-Farber Cancer Institute.

Dr. Kulke received the George Canellos Award for Clinical Investigation and the Ruth Brufsky Award for Pancreatic Cancer Research. He currently serves on the advisory board for the European Neuroendocrine Tumor Society, the executive committee of the North American Neuroendocrine Tumor Society, and chairs the Neuroendocrine Tumor Task force for the National Cancer Institute.

# # #